HK1202154A1 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment - Google Patents
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment Download PDFInfo
- Publication number
- HK1202154A1 HK1202154A1 HK15102546.8A HK15102546A HK1202154A1 HK 1202154 A1 HK1202154 A1 HK 1202154A1 HK 15102546 A HK15102546 A HK 15102546A HK 1202154 A1 HK1202154 A1 HK 1202154A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prediction
- coronary artery
- artery disease
- patients undergoing
- disease patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556915P | 2011-11-08 | 2011-11-08 | |
| US61/556,915 | 2011-11-08 | ||
| EP11188325.2A EP2592422A1 (en) | 2011-11-08 | 2011-11-08 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP11188325.2 | 2011-11-08 | ||
| PCT/EP2012/071973 WO2013068374A2 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202154A1 true HK1202154A1 (en) | 2015-09-18 |
Family
ID=45033776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102546.8A HK1202154A1 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9052327B2 (https=) |
| EP (2) | EP2592422A1 (https=) |
| JP (1) | JP6388284B2 (https=) |
| CN (1) | CN104024860B (https=) |
| CA (1) | CA2854422A1 (https=) |
| HK (1) | HK1202154A1 (https=) |
| WO (1) | WO2013068374A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9806270B2 (en) | 2011-03-25 | 2017-10-31 | Udc Ireland Limited | 4H-imidazo[1,2-a]imidazoles for electronic applications |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| KR102021099B1 (ko) | 2011-11-10 | 2019-09-16 | 유디씨 아일랜드 리미티드 | 전자장치 응용을 위한 4h-이미다조[1,2-a]이미다졸 |
| ES2552371T3 (es) * | 2012-05-25 | 2015-11-27 | Zora Biosciences Oy | Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9) |
| EP2872512B1 (en) | 2012-07-10 | 2017-05-10 | UDC Ireland Limited | Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications |
| CN106457090B (zh) | 2014-04-10 | 2020-09-29 | Mep马解决方案有限责任公司 | 粪便中寄生虫卵的定量方法 |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| WO2016100549A2 (en) * | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| US10184932B2 (en) | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| CN105628809B (zh) * | 2015-12-25 | 2018-04-03 | 中国药科大学 | 用于诊断区分冠状动脉粥样硬化和冠心病的代谢标志物 |
| CN105486773A (zh) * | 2015-12-25 | 2016-04-13 | 齐炼文 | 用于诊断冠心病的代谢标志物 |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| KR102003309B1 (ko) * | 2016-12-05 | 2019-07-25 | 한국과학기술연구원 | 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법 |
| CN107144648B (zh) * | 2017-04-26 | 2019-11-22 | 苏州海科医药技术有限公司 | 检测人血浆中匹伐他汀的液相色谱-串联质谱方法 |
| CN107014942A (zh) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测糖尿病冠心病的方法 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| WO2020092928A1 (en) * | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Compositions and methods for diagnosis of cardiovascular disease |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| CA3122035A1 (en) | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN109828076B (zh) * | 2019-04-11 | 2020-07-21 | 江南大学 | 一种高效薄层色谱联用生物发光法筛查贝特类降脂化学药掺伪的方法 |
| CN112630344B (zh) * | 2020-12-08 | 2021-12-14 | 河北医科大学第二医院 | 代谢标志物在脑梗死中的用途 |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
| CN113567583B (zh) * | 2021-07-22 | 2022-06-07 | 江南大学 | 应用固相萃取-超临界流体色谱-质谱法检测乳中极性脂的方法 |
| CN116087487B (zh) * | 2021-11-08 | 2025-06-03 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2293718A1 (en) * | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| US20100179066A1 (en) | 2007-06-07 | 2010-07-15 | Inserm (Institut National De La Santé Et De La Rec | Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia |
| EP2048243A1 (en) * | 2007-09-24 | 2009-04-15 | sanofi-aventis | Use of clec1B for the determination of cardiovascular and thrombotic risk |
| CN101939651A (zh) * | 2007-10-10 | 2011-01-05 | 保函医药公司 | 用于检测严重有害的心血管和脑血管事件的方法 |
| WO2009096903A1 (en) | 2008-01-28 | 2009-08-06 | National University Of Singapore | Lipid tumour profile |
| EP2265642A4 (en) * | 2008-03-12 | 2012-05-02 | Otago Innovation Ltd | BIOMARKERS |
| EP2265641B1 (en) * | 2008-03-12 | 2018-01-24 | Otago Innovation Limited | Biomarkers |
| CA2741117A1 (en) * | 2008-10-30 | 2010-05-06 | Centre De Recherche Public De La Sante | Biomarkers for heart failure |
| US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| JP5739898B2 (ja) * | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| AU2010324544A1 (en) | 2009-11-27 | 2012-06-21 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| NO2385374T3 (https=) * | 2010-05-05 | 2014-06-07 | ||
| CN103154742B (zh) * | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| EP2400573A1 (de) | 2010-06-23 | 2011-12-28 | Bayer MaterialScience AG | Elektromechanischer Wandler, Verfahren zu dessen Herstellung und Verwendung desselben |
| JP5980900B2 (ja) | 2011-04-08 | 2016-08-31 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| FI20115576A0 (fi) * | 2011-06-10 | 2011-06-10 | Teknologian Tutkimuskeskus Vtt Oy | Menetelmä Alzheimerin taudin diagnoimiseksi |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
-
2011
- 2011-11-08 EP EP11188325.2A patent/EP2592422A1/en not_active Withdrawn
-
2012
- 2012-11-07 JP JP2014540427A patent/JP6388284B2/ja active Active
- 2012-11-07 US US14/356,474 patent/US9052327B2/en active Active
- 2012-11-07 CA CA2854422A patent/CA2854422A1/en not_active Abandoned
- 2012-11-07 EP EP12784242.5A patent/EP2776842B1/en active Active
- 2012-11-07 WO PCT/EP2012/071973 patent/WO2013068374A2/en not_active Ceased
- 2012-11-07 HK HK15102546.8A patent/HK1202154A1/xx unknown
- 2012-11-07 CN CN201280054322.3A patent/CN104024860B/zh active Active
-
2015
- 2015-05-28 US US14/723,754 patent/US9459265B2/en active Active
-
2016
- 2016-08-29 US US15/249,935 patent/US20160363602A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104024860A (zh) | 2014-09-03 |
| US9052327B2 (en) | 2015-06-09 |
| EP2776842B1 (en) | 2017-07-12 |
| WO2013068374A3 (en) | 2013-07-18 |
| US9459265B2 (en) | 2016-10-04 |
| WO2013068374A2 (en) | 2013-05-16 |
| CA2854422A1 (en) | 2013-05-16 |
| JP2014532886A (ja) | 2014-12-08 |
| US20160363602A1 (en) | 2016-12-15 |
| JP6388284B2 (ja) | 2018-09-12 |
| EP2592422A1 (en) | 2013-05-15 |
| EP2776842A2 (en) | 2014-09-17 |
| US20150260738A1 (en) | 2015-09-17 |
| CN104024860B (zh) | 2017-06-06 |
| US20140295466A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013068374A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
| HK1202157A1 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
| WO2011161062A3 (en) | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | |
| NZ602056A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2012177945A3 (en) | Diagnostic methods for eosinophilic esophagitis | |
| NZ597273A (en) | Trimethylamine-containing compounds for diagnosis and prediction of disease | |
| WO2013190075A3 (en) | Specific biomarkers for hepatocellular carcinoma (hcc) | |
| WO2014037588A3 (en) | Methods and compounds for preventing, treating and diagnosing an inflammatory condition | |
| WO2009077864A3 (en) | Compositions and methods of detecting tiabs | |
| WO2011015944A3 (en) | Use of free dna as an early predictor of severity in acute pancreatitis | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| JP2016513094A5 (https=) | ||
| ECSP088081A (es) | Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente | |
| WO2007117444A3 (en) | Protein detection by aptamers | |
| NZ609824A (en) | Immunochromatography devices, methods and kits | |
| WO2009019367A3 (fr) | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal | |
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| EP2569635A4 (en) | METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY | |
| WO2014053996A3 (en) | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs | |
| WO2012050365A3 (ko) | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| WO2009099561A3 (en) | Urinary ca125 peptides as biomarkers of ovarian cancer | |
| WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
| FI3356826T3 (fi) | Gdf-15 melanooman diagnostisena markkerina | |
| WO2009019369A3 (fr) | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal |